| David I Davamony, PSYD | |
|
95 Mdg, Building 5522, 30 Nightingale Road, Edwards Afb, CA 93524-1730 | |
| (661) 277-5291 | |
| Not Available |
| Full Name | David I Davamony |
|---|---|
| Gender | Male |
| Speciality | Psychologist |
| Location | 95 Mdg, Building 5522, Edwards Afb, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366643371 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | PSY 21411 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| David I Davamony, PSYD 95 Mdg, Building 5522, 30 Nightingale Road, Edwards Afb, CA 93524-1730 Ph: (661) 277-5291 | David I Davamony, PSYD 95 Mdg, Building 5522, 30 Nightingale Road, Edwards Afb, CA 93524-1730 Ph: (661) 277-5291 |
News Archive
The University of Pennsylvania and AstraZeneca today announced a new collaborative research agreement to make use of their respective talents and resources in an effort to bridge the transition from drug discovery to development.
A new report launched today by the International Osteoporosis Foundation (IOF) in collaboration with the European Federation of Pharmaceutical Industry Associations (EFPIA) reveals that the burden of fractures in Europe has been vastly underestimated.
Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), today announced that the Company's Alpha IMS microchip was granted NUB innovation status and will now be reimbursed by Germany's statutory health insurance system.
On January 31, 2019, an 11-year old boy in Japan went to a medical clinic with a fever. The providers there diagnosed him with influenza, a strain called H3N2, and sent him home with a new medication called baloxavir.
Researchers from the John Theurer Cancer Center at Hackensack University Medical Center played an important role in a study that led to the Food & Drug Administration's (FDA) recent fast tracking of ipilimumab, a promising treatment for metastatic melanoma. The FDA based its decision largely on the results of a pivotal study published in the New England Journal of Medicine on August 19, 2010 – the same day the agency accepted Bristol-Myers Squibb's application for the drug's approval and granted the application priority review status.
› Verified 7 days ago
Dr. Nancyann N Cervantes, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 30 Nightingale Road Mental Health Clinic, Edwards Afb, CA 93524 Phone: 661-277-5291 Fax: 661-277-6327 |